A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma (TEACH)
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Shimin Sun Sun, MD
- Phone Number: 13701803117
- Email: jasmine.sun@antengene.com
Study Contact Backup
- Name: Xiaoqing Li, MA.Sc
- Phone Number: 13675893326
- Email: xiaoqing.li@antengene.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
Shanghai, Shanghai, China, 200032
- Fudan University Zhongshan Hospital
-
-
-
-
-
Kaohsiung, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital (CGMHKS)
-
Taichang, Taiwan, 40447
- China Medical University Hospital (CMUH)
-
Tainan, Taiwan, 70457
- National Cheng Kung University Hospital (NCKUH)
-
Taipei, Taiwan, 114
- Tri-Service General Hospital (TSGH)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained prior to any screening procedures and in accordance with local and institutional guidelines.
- Age ≥18 years.
- Patients with histologically or cytologically confirmed, NHL or advanced solid tumors which have progressed despite standard therapy, for whom no standard therapy exists, or who have refused standard therapy.
Patients must have objective evidence of PD on study entry:
- Advanced solid tumors: Measureable disease as defined by RECIST 1.11.
- NHL: Measureable disease including target lesion(s) as defined by the Cheson 2014 Classification2 for initial evaluation and staging.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Adequate hepatic function.
- Adequate renal function.
- Life expectancy of ≥ 3 months.
- Adequate hematopoietic function.
- Female patients of child-bearing potential must agree to use dual methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at Screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.
Exclusion Criteria:
- Female patients who are pregnant or lactating.
Time since the last prior therapy for treatment of advanced solid tumors or NHL**:
- Radiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anti-cancer therapy ≤ 4 weeks prior to C1D1.
- Palliative steroids for disease related symptoms within 7 days prior to C1D1.
- Known central nervous system metastases.
- Major surgery within 4 weeks before C1D1.
- Impaired cardiac function or clinically significant cardiac diseases.
- Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within 1 week prior to C1D1.
- Patients diagnosed with tuberculosis and had received treatment.
- Patients with a known history of human immunodeficiency virus (HIV).
- Known, active hepatitis A, B, or C infection.
- Serious psychiatric or medical conditions that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ATG-019 Alone
A starting does of 30 mg QoD×3 ATG-019
|
ATG-019 30 mg QoD×3 is selected as the staring dose.
Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
Other Names:
|
|
Experimental: ATG-019 + Niacin ER
A starting dose of 60 mg ATG-019 and 500 mg niacin ER
|
ATG-019 60 mg is selected as starting dose.
Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine MTD* or RP2D*
Time Frame: 18 months
|
MTD will be evaluated using the NCI-CTCAE, Version 5.0; RP2D will be determined by SMC for dose escalation phase.
|
18 months
|
|
To evaluate the Dose-Limiting Toxicity (DLT) for dose escalation phase
Time Frame: 18 months
|
DLTs will be evaluated using the CTCAE, Version 5.0 for grading.
|
18 months
|
|
Overall Response Rate (ORR)
Time Frame: 18 months
|
ORR analysis will be performed for both study phases by calculating the point estimate of the percentage of patients who have either CR or PR, presented as the number and percentage of patients, including a two-sided 95% CI.
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Plasma Concentration (Cmax)
Time Frame: 18 months
|
To determine the maximum plasma concentration (Cmax) for dose escalation phase.
|
18 months
|
|
Time to Reach Cmax (Tmax)
Time Frame: 18 months
|
To evaluate the time to reach Cmax after single and multiple doses for dose escalation phase.
|
18 months
|
|
To determine RP2D*
Time Frame: 18 months
|
RP2D will be determined by SMC for dose escalation phase.
|
18 months
|
|
Duration of response (DOR)
Time Frame: 18 months
|
The duration of time from first meeting CR or PR measurement criteria (whichever occurs first) until the first date that PD recurrence is objectively documented.
|
18 months
|
|
Disease control rate (DCR)
Time Frame: 18 months
|
The analysis of DCR will be similar to that described for ORR, for patients who achieve CR, PR, or SD for ≥ 8 weeks.
|
18 months
|
|
Progression-free survival (PFS)
Time Frame: 18 months
|
The duration of time from date of first dose of study treatment until the first date that PD is objectively documented or death due to any cause.
|
18 months
|
|
Overall Survival (OS)
Time Frame: 18 months
|
The duration of time from date of first dose of study treatment until death from any cause.
|
18 months
|
|
Time to progression (TTP)
Time Frame: 18 months
|
The duration of time from date of first dose of study treatment to date of PD.
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Stephen Xie, MD; PhD, Medical Monitor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Niacin
Other Study ID Numbers
Other Study ID Numbers
- ATG-019-STL-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.